TransCode Therapeutics Inc (RNAZ)
0.82
+0.11
(+15.98%)
USD |
NASDAQ |
May 03, 16:00
0.837
+0.02
(+2.07%)
After-Hours: 20:00
TransCode Therapeutics Cash from Operations (TTM): -2.315M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -2.315M |
| September 30, 2023 | -4.377M |
| June 30, 2023 | -5.293M |
| March 31, 2023 | -4.274M |
| December 31, 2022 | -3.709M |
| September 30, 2022 | -10.24M |
| June 30, 2022 | -8.882M |
| Date | Value |
|---|---|
| March 31, 2022 | -5.586M |
| December 31, 2021 | -2.160M |
| September 30, 2021 | -3.922M |
| June 30, 2021 | -0.9845M |
| March 31, 2021 | -0.997M |
| December 31, 2020 | -0.493M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-10.24M
Minimum
Sep 2022
-0.493M
Maximum
Dec 2020
-4.094M
Average
-3.922M
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
| Citius Pharmaceuticals Inc | -30.37M |
| NovaBay Pharmaceuticals Inc | -4.131M |
| Palatin Technologies Inc | -26.54M |
| iBio Inc | -18.89M |
| Theriva Biologics Inc | -19.00M |